Clinical Bioequivalence Study on Two Metoprolol Tablet 100mg Formulations

NCT ID: NCT03082352

Last Updated: 2019-07-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-31
• Study Completion Date: 2020-12-31

Brief Summary

The purpose of the study is to compare the bioavailability of a generic product of metoprolol with that of a reference product when administered to healthy volunteers under fasting conditions. The test product is BF-Metoprolol Tablets 100mg manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited and the reference product is Betaloc Tablet 100mg. The plasma kinetic data of metoprolol obtained from two formulations will be used to access the interchangeability of the products.

Detailed Description

The study design is a single-dose, two-treatment, two-period, two-sequence cross over with a washout period of one to two weeks. Subject will be randomly assigned to two groups corresponding to two dosing sequences. Each subject will undergo two study (treatment) sessions, during which a single oral dose of 100mg metoprolol from either test or reference formulations will be administered. The estimated duration of subject's participation will be about 29-36 days (i.e. 3 weeks for screening and medication restraint, 1 day each for study (treatment) sessions I and II, 1 - 2 weeks as washout period. Venous blood samples will be collected at pre-dose (0h), and up to 24h post dose. The plasma concentrations of metoprolol will be determined by a validated assay. The non-compartmental method will be used to analyze the plasma concentration-time data and calculate the main pharmacokinetic parameters such as Cmax, Tmax, AUC0-last, AUC0-inf, and T1/2. ANOVA will be calculated on logarithmically transformed Cmax, AUC0-last and AUC0-inf. The two one sided tests will be used to calculate the 90% confidence intervals for the mean difference in AUC0-last, AUC0-inf and Cmax and to assess the bioequivalence of the two products

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

BF-Metoprolol Tablet 100mg

During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours

Group Type: EXPERIMENTAL

BF-Metoprolol Tablet 100mg

Intervention Type: DRUG

BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Betaloc Tablet 100mg

During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours

Group Type: ACTIVE_COMPARATOR

Betaloc Tablet 100mg

Intervention Type: DRUG

Betaloc Tablet 100mg will be used as a comparator drug for the BE study

Interventions

BF-Metoprolol Tablet 100mg

BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention Type: DRUG

Betaloc Tablet 100mg

Betaloc Tablet 100mg will be used as a comparator drug for the BE study

Intervention Type: DRUG

Other Intervention Names

Metoprolol Tablet 100mg; Metoprolol Tablet 100mg

Eligibility Criteria

Inclusion Criteria

• Male and non-pregnant female, 18 to 55 years of age
• Body Mass Index between 18 to 30 kg/m2
• Accessible vein for blood sampling
• High probability for compliance and completion of the study
• Female subjects must agree to practice abstinence or take effective contraceptive methods to prevent pregnancy from the start of the screening and until two weeks of last dose administration

Exclusion Criteria

• Clinically significant hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to the study
• Clinically significant abnormality in physical examination, vital sign, laboratory test results, ECG evaluation, urine test, blood chemistry or haematological test
• Regular consumption of tobacco used in any forms
• Regular consumer of alcohol (more than one drink per day)
• Blood donation within 4 weeks prior to the start of the study
• Use of metoprolol within 4 weeks before the study
• Use of antihypertensive medications or other beta blockers within 4 weeks before the study
• Volunteer in any other clinical drug study within 2 months prior to this study
• Hypersensitivity to metoprolol or other drugs in its class
• History of drug abuse in any form
• Female subjects who are breastfeeding or pregnant

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: collaborator

Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zhong Zuo

Role: PRINCIPAL_INVESTIGATOR

School of Pharmacy, The Chinese University of Hong Kong

Riza Ozaki

Role: STUDY_DIRECTOR

Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong

Brian Tomlinsion

Role: STUDY_DIRECTOR

Department of Medicine and Therapeutics, The Chinese University of Hong Kong

Central Contacts

Evelyn YM Chau

Role: CONTACT

bfok@cuhk.edu.hk

(852) 26323377

Benny SP Fok

Role: CONTACT

bfok@cuhk.edu.hk

(852) 26323377

Other Identifiers

BABE-P15-100

Identifier Type: -

Identifier Source: org_study_id